Can-Fite BioPharma (CANF) announced that a patient currently treated with Namodenoson in a compassionate use program in Can-Fite’s Phase II Liver Cancer Study has an overall survival time of 8 years with a complete response. The patient, who suffered from advanced liver cancer was enrolled in the former Can-Fite Phase II study, continue to be treated with Namodenoson, and has now an overall survival of 8 years, with disappearance of ascites, normal liver function, good quality of life and is defined as a long term complete response.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CANF:
- CANF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Can-Fite BioPharma Advances in Pancreatic Cancer Trial
- Can-Fite BioPharma doses first patient in Phase IIa trial
- Can-Fite BioPharma Secures Australian Patent for Obesity Drug
- Can-Fite BioPharma announces an update related to IP status of Namodenoson
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
